Afuco™ Anti-PDCD1 ADCC Therapeutic Antibody (Nivolumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human PDCD1. Nivolumab is a fully human IgG4 monoclonal antibody for the treatment of cancer. Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-770 |
| Pricing | Inquiry |
| Host | Human |
| Target | PDCD1 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IF, IP, Neut, FuncS, ELISA, FC |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |